ArticleBMC cancer2025
The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDaratumumab (Dara), a humanized IgGκ monoclonal antibody targeting CD38, has shown significant efficacy in the treatment of multiple myeloma (MM). However, its impact on myeloma bone disease (MBD) and skeletal-related events (SREs) remains inadequately explored. Elucidating the effect of Dara on the incidence of SREs is of considerable clinical importance for MM management.
methodsWe conducted a multicenter retrospective analysis of 164 newly diagnosed MM (NDMM) patients who received first-line treatment with or without Dara-based regimens between December 2019 and December 2023. The primary endpoint was the incidence of first SRE within 6 months. Subgroup analyses were performed based on risk stratification, baseline hypercalcemia, extramedullary disease, circulating plasma cells, and use of anti-bone resorption drugs. Statistical analyses included Kaplan-Meier survival curves, log-rank tests, and Cox proportional hazards models with adjustment for covariates.
resultsThe overall incidence of SREs was 17.68% (29/164), with 9.80% (5/51) in the Dara group and 21.23% (24/113) in the control group (log-rank P = 0.08). Univariable and multivariable Cox regression analyses consistently showed a non-significant reduction in SRE risk with Dara-based treatment (HR = 0.44, 95% CI: 0.17-1.15, P = 0.09; adjusted HR = 0.47, 95% CI: 0.17-1.28, P = 0.14). Subgroup analyses revealed a significant benefit of Dara in patients without baseline hypercalcemia (HR = 0.19, 95% CI: 0.05-0.81, P = 0.02) and a suggestive benefit in the standard-risk subgroup (log-rank P < 0.05). A significant interaction was observed between Dara use and hypercalcemia status (P for interaction = 0.03).
conclusionsWhile Dara-based treatment did not significantly reduce SRE incidence in the overall cohort, it may provide protective benefits against SREs in specific subgroups, particularly among patients without hypercalcemia. Our finding warrants further investigation into the bone-protective effects of Dara in MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.